GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
O

Orum Therapeutics 475830.KQ · KRW

N/A · KOSDAQ · 🇰🇷 South Korea

Compare

14,420

-1.23%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Orum Therapeutics

Its shares trade on KOSDAQ under the ticker 475830.KQ. It has been listed since 14 February 2025. In the fiscal year to 31 December 2025, it reported revenue of ₩23.6m and a net loss of ₩41.97bn. At that date it held total assets of ₩169.32bn and shareholders' equity of ₩130.89bn.

Orum Therapeutics Inc is a KR-based company operating in industry. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2025-02-14. Orum Therapeutics Inc is a Korea-based company principally engaged in the research and development of biopharmaceuticals. The firm is principally engaged in the research and development of new biopharmaceuticals for cancer and immune diseases based on its platforms.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
14 Feb 2025
Website
orumrx.com ↗

Leadership

Pay as last reported

  • Mr. Sung Joo LeeChief Executive Officer, Founder, Director
  • Ms. Jae Won KimChief Financial Officer
  • Mr. Peter ParkChief Scientific Officer
  • Mr. Nate FishkinVice President, Head Of Chemistry
  • Mr. Olaf ChristensenChief Medical Officer
  • Mr. James PalacinoHead of Biology

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • KR-based company with headquarters in Daejeon for biopharmaceutical R&D
  • Focus on cancer and immune disease treatments using advanced platforms
  • IPO on 14 February 2025 marks significant market entry

Weaknesses

  • KR-based company with headquarters in Daejeon for biopharmaceutical R&D
  • Focus on cancer and immune disease treatments using advanced platforms
  • IPO on 14 February 2025 marks significant market entry

Opportunities

  • KR-based company with headquarters in Daejeon for biopharmaceutical R&D
  • Focus on cancer and immune disease treatments using advanced platforms
  • IPO on 14 February 2025 marks significant market entry

Threats

  • KR-based company with headquarters in Daejeon for biopharmaceutical R&D
  • Focus on cancer and immune disease treatments using advanced platforms
  • IPO on 14 February 2025 marks significant market entry

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.